ClinicalTrials.gg
SuspendedNCT04300335Updated Oct 9, 2026

The Feasibility and Effects of Exercise on Patients Suffering From Multiple Myeloma

An interventional study of Individual Exercise and Group Exercise in Multiple Myeloma, sponsored by Medical University of Vienna. Suspended at 1 site in Austria. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by Medical University of Vienna · Not applicable, Interventional, and Supportive care

How we know

Why this study was suspended
The study was not started because the necessary resources could not yet be secured after COVID-19, which was the reason for the initial interruption of the study.
Updated Oct 9, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
45
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 92 studies in Multiple Myeloma with a site in Austria — 10 open to participants now, 26 under way, 21 of them phase 3. Multiple Myeloma · Austria.

Planned enrollment
70th of 77
45 · median 452
Started
2027
the only one that year
No phase
Only one
of the 92
Registered
61st of 92
by date

Among the 92 studies in Multiple Myeloma with a site in Austria, this one is the 70th largest by planned enrollment of the 77 interventional ones that give a count, is the only one that started in 2027, is the only one with no phase, and was the 61st registered.

Multiple Myeloma

3,764 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

10 of the 92 studies in Multiple Myeloma with a site in Austria are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in Austria have not opened yet or have stopped. Only those recruiting at a site in Austria →

Who these studies take

Of the 583 Multiple Myeloma studies recruiting now, 428 (73%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 92 studies in Multiple Myeloma with a site in Austria, or all of them as a file.
02

Study summary

Multiple myeloma is the second most common haematological cancer with a cancer incidence of around 500 new cases in Austria per year . Novel treatment methods have significantly increased the cancer-specific survival rate in patients with multiple myeloma. For Austria, this means that 5- and 10-year survival rates rose from 32.1 to 46.4% and from 19.0 to 25.6% from the end of the 1980s to the end of the 2000s.

Longer survival is associated with the need to maintain independence and quality of life in the longer term. In this context, regular physical training has seen a significant increase in the importance of cancer in recent years.The guidelines of the American College of Sports Medicine still contain very general training recommendations for cancer patients. Either 150 minutes of moderate or 75 minutes of intensive endurance training per week are recommended, supplemented by at least two units of strengthening training and stretching exercises for the large muscle groups.

In a recent cross-sectional and pilot study with multiple myeloma patients that was carried out at the Clinic for Physical Medicine, Rehabilitation and Occupational Medicine at the Medical University of Vienna (EK 1725/2018), it was on the one hand identified that there was a discrepancy between these patients on the one hand has given actual and perceived risk of falling, and on the other hand it is concluded that training recommendations should be carried out separately in group and individual training according to the actual risk of falling and fracture.

The present project is the follow-up to this cross-sectional investigation. The aim is to examine the feasibility and effects of a structured, physical training program carried out over a period of 12 weeks on physical performance, quality of life, body composition and the risk of falling. The effects of patients with increased risk in individual training sessions are compared to those of lower risk patients in group training sessions. Furthermore, the study patients will be able to bring training partners with them to their own training units if available and for their own security. They are evaluated separately according to qualitative criteria.

Read the detailed description

The aim of this study is to investigate the feasibility and effectiveness of individualized training support for multiple myeloma patient populations divided into high and low risk according to their fall and fracture risk. The primary hypothesis is that multiple myeloma patients who meet the criteria for a high risk of falling and / or fracture can achieve equivalent adherence rates and training effects through individually compiled individual training, such as multiple myeloma patients with low risk of falling who conduct group training.

The adherence rates are recorded via attendance lists for training and video conferences as well as a training diary for independent training. To record the training effects, physical performance and functionality are measured and the quality of life, sexuality, depression, fatigue, sleep quality, work ability and risk of falling are assessed using standardized, validated questionnaires.

03

Conditions studied

  • Multiple Myeloma

Keywords

  • exercise
  • fracture risk
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Multiple Myeloma after primary Treatment
  • Sufficient knowledge of the German language to being able to follow the study procedures
  • Cardiologic-internal clearance for exercise

Exclusion criteria

Exclusion Criteria:

  • Fulfillment of absolute exclusion criteria of the cardiovascular system or on the musculoskeletal system with regard to physical trainability
  • Insufficient language knowledge
  • Cognitively unable to follow the course of the study
  • Severe mental illness
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
45 participants (estimated)

Study arms

  • Experimental
    High Risk - Individual Exercise

    Patients who show an increased fracture risk and/or increased risk of fall in the screening assessments and are therefore allocated to an individualized personal training.

    Other: Individual Exercise

  • Experimental
    Low Risk - Group Exercise

    Patients who show neither increased fracture risk nor increased risk of fall in the screening assessments and are therefore allocated to the exercise group.

    Other: Group Exercise

Interventions

  • OtherIndividual Exercise

    Supervised body weight \& resistance band resistance exercises in a one-on-one personal training setting plus home based aerobic exercise

  • OtherGroup Exercise

    Supervised body weight \& resistance band resistance exercises in a Group setting plus home based aerobic exercise

06

What researchers measure

Primary outcomes

  1. Feasibility (Adherence)

    We hypothesize that the adherence of "High Risk Patients" to a personal, individualized exercise intervention is equal to that of "Low Risk Patients" performing group exercise.

    Time frame: Adherence rates through 12 weeks of exercise intervention program

Secondary outcomes

  1. VO2max

    Maximum oxygen consumption in a cardiopulmonary exercise testing

    Time frame: Baseline + 12 weeks

  2. Handgrip Strength (HGS)

    Handgrip Dynamometer (JAMAR)

    Time frame: Baseline + 12 weeks

  3. Six Minute Walk Test (6MWT)

    Distance covered when walking as fast as possible in six minutes

    Time frame: Baseline + 12 weeks

  4. Tinetti-Test/Performance Oriented Mobility Assessment (POMA)

    Risk of Fall Assessment

    Time frame: Baseline + 12 weeks

  5. Timed up and Go Test (TUG)

    Risk of Fall Assessment

    Time frame: Baseline + 12 weeks

  6. Bioimpedance Analysis (BiA)

    Body Composition measurement measured with Nutribox (BiA)

    Time frame: Baseline + 12 weeks

  7. Five Repetitions Sit-to-Stand Test (5STS)

    Test for Lower Extremity Strength (time needed to stand up and sit down on a chair 5 times)

    Time frame: Baseline + 12 weeks

Other outcomes

  1. European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Basic Module (EORTC QLQ-C30)

    Cancer specific quality of life (Questionnaire); Score range from 0 to 100; A high scale score represents a higher response level. Thus a high score for a functional scale represents a high / healthy level of functioning, a high score for the global health status / QoL represents a high QoL, but a high score for a symptom scale / item represents a high level of symptomatology / problems.

    Time frame: Baseline + 12 weeks

  2. European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Myeloma Module (EORTC QLQ-MY20)

    Multiple myeloma specific quality of life (Questionnaire); Score range from 0 to 100; A high scale score represents a higher response level. Thus a high score for a functional scale represents a high / healthy level of functioning, a high score for the global health status / QoL represents a high QoL, but a high score for a symptom scale / item represents a high level of symptomatology / problems.

    Time frame: Baseline + 12 weeks

  3. European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Fatigue Module (EORTC QLQ-FA12)

    Cancer related fatigue specific quality of life (Questionnaire); Score range from 0 to 100; A high scale score represents a higher response level. Thus a high score for a functional scale represents a high / healthy level of functioning, a high score for the global health status / QoL represents a high QoL, but a high score for a symptom scale / item represents a high level of symptomatology / problems.

    Time frame: Baseline + 12 weeks

  4. European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Sexual Health Quality Module (EORTC QLQ-SHQ22)

    Cancer related sexual health specific quality of life (Questionnaire); Score range from 0 to 100; A high scale score represents a higher response level. Thus a high score for a functional scale represents a high / healthy level of functioning, a high score for the global health status / QoL represents a high QoL, but a high score for a symptom scale / item represents a high level of symptomatology / problems.

    Time frame: Baseline + 12 weeks

  5. International Physical Activity Questionnaire (IPAQ)

    Physical Activity (Questionnaire); Patients are asked about the frequency and volume of at least 10 minutes long episodes of vigorous and moderate physical activity during their last 7 days. Higher values indicate higher levels of physical activity.

    Time frame: Baseline + 12 weeks

  6. Hospital Anxiety and Depression Scale (HADS)

    Anxiety and Depression (Questionnaire); Score range from 0-21; lower scores indicating lower levels anxiety and depression

    Time frame: Baseline + 12 weeks

  7. Work Ability Index (WAI)

    Work Ability (Questionnaire); Score range 1-10; higher scores indicating higher work ability

    Time frame: Baseline + 12 weeks

  8. Pittsburgh Sleep Quality Index (PSQI)

    Sleep Quality (Questionnaire); score range from 0 to 21; lower scores indicating healthier sleep quality

    Time frame: Baseline + 12 weeks

  9. Falls Efficacy Scale (FES)

    Fall Risk Assessment (Questionnaire); score range from 16 to 64; higher values indicate less fall-related self-efficacy (and more concern about falling).

    Time frame: Baseline + 12 weeks

07

Study locations

1 site
  • Medical University of Vienna
    Vienna, 1090, Austria
08

References and documents

Publications

  • Radocha J, Hajek R, Brozova L, Pour L, Spicka I, Minarik J, Gregora E, Jungova A, Jelinek T, Heindorfer A, Sykora M, Maisnar V. Simplified novel prognostic score for real-life older adults with multiple myeloma-registry-based analysis. Ann Hematol. 2019 Apr;98(4):951-962. doi: 10.1007/s00277-018-3568-2. Epub 2018 Dec 11. PubMed 30539278 ↗
  • Warren JL, Harlan LC, Stevens J, Little RF, Abel GA. Multiple myeloma treatment transformed: a population-based study of changes in initial management approaches in the United States. J Clin Oncol. 2013 Jun 1;31(16):1984-9. doi: 10.1200/JCO.2012.46.3323. Epub 2013 Apr 8. PubMed 23569317 ↗
  • Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S, Kapoor P, Dingli D, Hayman SR, Leung N, Lust J, McCurdy A, Russell SJ, Zeldenrust SR, Kyle RA, Rajkumar SV. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014 May;28(5):1122-8. doi: 10.1038/leu.2013.313. Epub 2013 Oct 25. PubMed 24157580 ↗
  • Mock V, Pickett M, Ropka ME, Muscari Lin E, Stewart KJ, Rhodes VA, McDaniel R, Grimm PM, Krumm S, McCorkle R. Fatigue and quality of life outcomes of exercise during cancer treatment. Cancer Pract. 2001 May-Jun;9(3):119-27. doi: 10.1046/j.1523-5394.2001.009003119.x. PubMed 11879296 ↗
  • Crevenna R. Aspects of cancer rehabilitation: an Austrian perspective. Disabil Rehabil. 2020 Jan;42(1):1. doi: 10.1080/09638288.2018.1522554. Epub 2019 Jan 27. No abstract available. PubMed 30686037 ↗
  • Crevenna R. Cancer rehabilitation and palliative care--two important parts of comprehensive cancer care. Support Care Cancer. 2015 Dec;23(12):3407-8. doi: 10.1007/s00520-015-2977-1. Epub 2015 Oct 6. No abstract available. PubMed 26441078 ↗
  • Schmitz KH, Courneya KS, Matthews C, Demark-Wahnefried W, Galvao DA, Pinto BM, Irwin ML, Wolin KY, Segal RJ, Lucia A, Schneider CM, von Gruenigen VE, Schwartz AL; American College of Sports Medicine. American College of Sports Medicine roundtable on exercise guidelines for cancer survivors. Med Sci Sports Exerc. 2010 Jul;42(7):1409-26. doi: 10.1249/MSS.0b013e3181e0c112. PubMed 20559064 ↗
  • Cenik F, Keilani M, Hasenohrl T, Huber D, Stuhlpfarrer B, Pataraia A, Crevenna R. Relevant parameters for recommendations of physical activity in patients suffering from multiple myeloma : A pilot study. Wien Klin Wochenschr. 2020 Mar;132(5-6):124-131. doi: 10.1007/s00508-019-01582-z. Epub 2019 Nov 29. PubMed 31784826 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Sep 2027; primary completion for Mar 2028, 6 months later.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 9, 2026: start Mar 2026 → Sep 2027, primary completion Oct 2026 → Mar 2028 and completion Dec 2026 → Jul 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 2, 2020
First posted
Mar 9, 2020
StartEst.
Sep 1, 2027was Mar 2026
Primary completionEst.
Mar 31, 2028was Oct 2026
CompletionEst.
Jul 31, 2028was Dec 2026
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Mar 2026→Sep 1, 2027
Oct 9, 2026
Primary completion
Oct 2026→Mar 31, 2028
Oct 9, 2026
Study completion
Dec 2026→Jul 31, 2028
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    Start date Mar 2026→Sep 1, 2027
    Primary completion Oct 2026→Mar 31, 2028
    Study completion Dec 2026→Jul 31, 2028
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04300335
Responsible party
Richard Crevenna (Univ.-Prof. Dr. Richard Crevenna, MBA, MMSc, Head of the Department of Physical Medicine, Rehabilitation and Occupational Medicine, Medical University of Vienna) — Principal investigator
First posted
Mar 9, 2020
Start date
Sep 1, 2027 (estimated)
Primary completion
Mar 31, 2028 (estimated)
Completion
Jul 31, 2028 (estimated)
Last update
Oct 9, 2026

Study contacts

Richard Crevenna, Prof. MD
principal investigator · Medical University of Vienna

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is suspended, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion